GURU.Markets stock price, segment price, and overall market index valuation
The company's share price TXG
10x Genomics is a leader in single-cell analysis tools that have revolutionized biological research. Its stock price reflects scientists' demand for its high-end instruments and consumables, but also its intense competition and dependence on scientific funding.
Share prices of companies in the market segment - Dna
10x Genomics is a leader in single-cell analysis tools. Its core business is sales of instruments and consumables. We classify it as part of the DNA sector, and the chart below reflects the dynamics of the entire industry, which is dependent on research spending.
Broad Market Index - GURU.Markets
10x Genomics is a leader in single-cell analysis technologies that enable scientists to study biology at an unprecedented level. It is a component of the GURU.Markets index. The chart below represents the market. See how 10x Genomics stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
TXG - Daily change in the company's share price TXG
Shares of 10x Genomics, a genomics company, exhibit high volatility, as measured by change_co. This metric reflects sensitivity to scientific breakthroughs and research spending. This metric is important for formulas on System.GURU.Markets for analyzing the innovative biotech sector.
Daily change in the price of a set of shares in a market segment - Dna
10x Genomics, Inc. is a leader in single-cell analysis. This chart highlights the high volatility of the life sciences sector. Comparing it to TXG's performance helps us understand how much its growth depends on R&D budgets and the adoption of its technology in research labs.
Daily change in the price of a broad market stock, index - GURU.Markets
10x Genomics is a leader in spatial and single-cell genomics technologies. Its equipment is the foundation for breakthrough research. The chart below shows overall market volatility, which can be used to assess how the market is responding to breakthrough biotech technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization TXG
10x Genomics is a leader in spatial biology technologies that enable the analysis of cells in their natural environment. Its year-over-year growth is a barometer of R&D investment in the biotech industry. The chart below tells the story of this science-intensive business.
Annual dynamics of market capitalization of the market segment - Dna
10x Genomics, Inc. is a leader in single-cell analysis technologies that enable scientists to study biology at an unprecedented level. Its tools have become the standard in research. The graph shows how its technological dominance and reliance on R&D budgets influence its rapid growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
10x Genomics, with its single-cell analysis technology, is a gold mine for biotech. Demand for its equipment is driven by R&D budgets, not economics. The company's stock price is a long-term growth story, driven by the fact that its technology is needed to create breakthrough drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization TXG
10x Genomics, a leader in single-cell analysis tools that enable unprecedented biology research, is a leader in single-cell analysis. The monthly fluctuations in the chart reflect the R&D budgets of the biotech companies and research institutes that are the primary customers of its systems.
Monthly dynamics of market capitalization of the market segment - Dna
10x Genomics produces tools and reagents for genomic analysis, enabling scientists to study biology at the single-cell level. Their technology is revolutionizing biomedical research. The graph below illustrates the overall dynamics of the life sciences sector, where 10x Genomics is a supplier of key equipment for discovery.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
10x Genomics creates tools that enable scientists to analyze biology at the cell level, revolutionizing research. As a growth technology company, it is sensitive to market sentiment, as reflected in the chart. Against this backdrop, it's interesting to analyze how the consistent demand for its unique platforms from the scientific community has influenced its performance.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization TXG
Shares of 10x Genomics, a company that creates tools for analyzing single cells, reflect the cutting edge of biological research every week. The stock price reflects the pace of adoption of its technology in laboratories around the world seeking to understand diseases at the cellular level.
Weekly dynamics of market capitalization of the market segment - Dna
Genomic technologies is a sector where weekly dynamics reflect the pace of scientific discovery. Demand for DNA and cell analysis tools from research labs is a common driver. The chart illustrates this backdrop, which allows one to appreciate 10x Genomics' technological leadership.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
10x Genomics is a leader in single-cell analysis technologies that has revolutionized biology. As a disruptive technology company, its stock can be highly volatile. This chart will show whether 10x Genomics is living its life by responding to scientific breakthroughs, or whether its high valuation makes it vulnerable to overall market volatility.
Market capitalization of the company, segment and market as a whole
TXG - Market capitalization of the company TXG
The market capitalization of 10x Genomics tells the story of a company that created tools for analyzing biology at the cell level. Its chart reflects the scientific revolution it has unleashed. Its volatile performance reflects the enormous potential of its technology in medicine, coupled with its high research costs and challenging path to profitability.
TXG - Share of the company's market capitalization TXG within the market segment - Dna
10x Genomics is a leader in single-cell analysis technologies that enable scientists to study biology at an unprecedented level of resolution. Its dominant market share reflects its technological breakthrough. The chart shows the weight of this company, whose tools are revolutionizing biology and medicine.
Market capitalization of the market segment - Dna
10x Genomics is a leader in single-cell analysis tools, revolutionizing biological research. The chart below shows the market capitalization of the life sciences sector. Its growth reflects the increasing complexity and detail of biological research, where 10x technology has become indispensable.
Market capitalization of all companies included in a broad market index - GURU.Markets
10x Genomics is a leader in single-cell analysis technologies that enable scientists to study cells at an unprecedented level. Its market capitalization reflects the revolution in biology. The chart below shows the economic weight of companies creating scientific tools.
Book value capitalization of the company, segment and market as a whole
TXG - Book value capitalization of the company TXG
10x Genomics's balance sheet consists of its factories producing instruments and reagents for genomic analysis, as well as a vast patent portfolio. This is real, science-intensive capital that allows scientists to study cells at an unprecedented level. How has this revolutionary, yet expensive, asset grown? The chart below shows the dynamics.
TXG - Share of the company's book capitalization TXG within the market segment - Dna
10x Genomics produces equipment and reagents for single-cell analysis, relying on its own R&D centers and production lines. The chart shows the share of these high-tech tangible assets, reflecting the physical foundation upon which the genomics revolution is built.
Market segment balance sheet capitalization - Dna
As the BCap_Seg graph shows, creating tools for genomic research is high-tech and capital-intensive. 10x Genomics, a leader in this field, invests heavily in R&D and manufacturing infrastructure to create its sophisticated instruments and reagents, creating a high barrier to entry.
Book value of all companies included in the broad market index - GURU.Markets
10x Genomics' assets are not drugs, but factories and laboratories producing instruments and reagents for genomic analysis. Their book value reflects the physical scale of production, which supplies scientists around the world with tangible "microscopes" for studying biology at the level of individual cells.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - TXG
10x Genomics produces equipment and reagents for single-cell analysis, revolutionizing biology. Its value lies not in its manufacturing plants, but in its technology platform and patents. The MvsBCap chart demonstrates a high premium for technological leadership. Its dynamics reflect the pace of adoption of its technology in scientific labs and pharmaceutical companies worldwide.
Market to book capitalization ratio in a market segment - Dna
10x Genomics creates tools for analyzing biological systems at the single-cell level. Its value lies in its breakthrough technology and patents. The chart shows the significant premium investors pay for its technological leadership in genomics, not the cost of its equipment.
Market to book capitalization ratio for the market as a whole
10x Genomics produces equipment and reagents for genomic analysis. It's a company creating tools for scientific revolution. Its value lies in its technology and patents, not its manufacturing plants. This chart clearly demonstrates the enormous premium the market is willing to pay for companies whose products become standards in cutting-edge scientific fields.
Debts of the company, segment and market as a whole
TXG - Company debts TXG
10x Genomics, a leader in single-cell analysis, uses capital to fund cutting-edge research and development, as well as global commercial expansion. The technological race in genomics requires massive investments. This chart shows how the company is investing in science that is changing our understanding of biology and medicine, driving its growth.
Market segment debts - Dna
10x Genomics is a leader in single-cell analysis technologies, revolutionizing biological research. Rapid growth in the life sciences sector requires significant investment in R&D and manufacturing. This chart illustrates how the company funds its innovation and business scaling, and compares its approach with other tech companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio TXG
10x Genomics produces innovative systems for single-cell analysis, revolutionizing biology. The chart shows how the company finances its cutting-edge technologies. For a leader in an emerging scientific field requiring significant R&D investment, its capital structure reflects a balance between the speed of innovation and financial strength.
Market segment debt to market segment book capitalization - Dna
10x Genomics produces equipment and reagents for genomic analysis, being at the forefront of the biotech revolution. This metric, for a science-intensive industry, reflects how much capital is raised to fund R&D. It helps understand whether a company's debt is an investment in technological leadership or a sign of high operating expenses.
Debt to book value of all companies in the market
10x Genomics operates at the forefront of biotechnology. This chart reflects the overall risk appetite in the economy. For a company burning capital for future discoveries, it helps understand how its risky funding model compares to the overall market conditions and investors' willingness to wait.
P/E of the company, segment and market as a whole
P/E - TXG
This chart of 10x Genomics, a provider of genomics research equipment, is a barometer of the biotech industry. High readings indicate investor confidence that the company's technologies will become standard in scientific laboratories and pharmaceuticals, opening new horizons in medicine and positioning the company for long-term growth.
P/E of the market segment - Dna
This chart shows the average price-to-earnings ratio for the scientific equipment sector, where 10x Genomics is a leader. The industry's high valuation reflects faith in the biotech revolution. This metric helps us understand whether 10x Genomics' premium valuation is justified given overall expectations for the genomics research sector.
P/E of the market as a whole
10x Genomics, Inc. creates tools for analyzing biological systems at single-cell resolution, revolutionizing research in oncology and immunology. This technology is key to science. This overall market sentiment chart allows you to compare 10x Genomics's lofty valuation with the market and understand whether it is a justified bet on the future of biological research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company TXG
10x Genomics produces innovative equipment and reagents for genomic analysis at the single-cell level. The chart demonstrates high investor expectations for future revenue, which depend on the pace of implementation of its technology in scientific research and pharmaceuticals. This is a bet on breakthroughs in understanding biology and treating diseases.
%20P%2FE%20TXG&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-TXG&v=1772570629082 "Chart of the company's future (projected) P/E TXG")
Future (projected) P/E of the market segment - Dna
10x Genomics produces tools and software for single-cell analysis, revolutionizing biological research. Average profitability expectations for the sector are shown here. This helps us understand how much investors believe 10x Genomics' technology will become the gold standard in science and lead to financial success.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772570629160 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
10x Genomics produces equipment and reagents for single-cell analysis, revolutionizing biological research. It's a company shaping a new market. This overall risk appetite chart shows how much investors are willing to pay for cutting-edge technologies that could transform science and medicine over the long term.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772570629217 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit TXG
10x Genomics, Inc. provides cutting-edge tools for biological research, enabling scientists to analyze cells at an unprecedented level. The company's revenue depends on sales of its instruments and consumables to research institutions and pharmaceutical companies. This chart illustrates how investments in scientific progress worldwide drive the company's financial growth.
Profit of companies in the market segment - Dna
10x Genomics, Inc. provides cutting-edge tools for single-cell analysis, enabling scientists to make breakthroughs in biology and medicine. Its technologies have become standard in many laboratories. This chart shows overall profitability in the life sciences sector, where providers of innovative tools and platforms are benefiting from rising R&D spending across the industry.
Overall market profit
10x Genomics, Inc. produces single-cell analysis tools, revolutionizing biotechnology. The company's growth is driven by the speed of scientific discoveries and the adoption of its technologies by research labs and pharmaceutical companies. This process is not dependent on short-term economic cycles, as shown by this chart, but follows a long-term trend.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company TXG
10x Genomics provides integrated systems for single-cell analysis, revolutionizing biological research. Future revenue depends on research budgets and the pace of adoption of its technology in laboratories worldwide. This chart reflects analysts' expectations for growth in the advanced life sciences sector.
%20profit%20of%20the%20company%20TXG&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-TXG&v=1772570629437 "Graph of future (projected) profit of the company TXG")
Future (predicted) profit of companies in the market segment - Dna
10x Genomics provides cutting-edge tools for single-cell analysis, enabling scientists to make breakthroughs in oncology, immunology, and neuroscience. The company is a key player in the single-cell genomics revolution. This chart shows revenue expectations for the biotech sector, reflecting how 10x Genomics' technologies are impacting the entire industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772570629467 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
10x Genomics, Inc. creates tools for analyzing biological systems at the single-cell level. Its products are used in scientific research. Demand depends on biotechnology R&D budgets. This economic outlook influences public and private research funding, which 10x Genomics depends on.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772570629488 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - TXG
10x Genomics produces single-cell analysis tools, revolutionizing biological research. As a leader in this emerging technology niche, revenue growth is a key metric. This chart reflects the high expectations of investors for the future adoption of its technology in laboratories worldwide.
P/S market segment - Dna
10x Genomics is a life sciences technology company that has revolutionized biological research with its single-cell and spatial genome analysis tools. Their technologies allow scientists to see diseases with unprecedented clarity. This chart represents the average revenue estimate for the sector, reflecting expectations for 10x Genomics' breakthrough technologies.
P/S of the market as a whole
10x Genomics develops and markets tools for single-cell analysis, revolutionizing biotechnology. The company's products are indispensable for many researchers. This chart shows how highly the market values the revenue of this company, which provides breakthrough scientific technologies, compared to the market average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company TXG
10x Genomics produces tools and software for single-cell analysis, revolutionizing biotechnology. For a company developing a new technology platform, valuation based on future revenue is critical. It demonstrates investors' confidence in the widespread adoption of this technology in scientific research and medicine, which should lead to exponential sales growth.
%20P%2FS%20TXG&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-TXG&v=1772570629749 "The graph of the company's future (projected) P/S TXG")
Future (projected) P/S of the market segment - Dna
10x Genomics provides integrated systems for single-cell analysis, enabling researchers to gain a deeper understanding of biology and disease. This chart compares the company's estimated future sales with expectations for the life sciences sector. It shows whether investors believe its technology will become the standard in genomic research and applied medicine, driving long-term growth.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772570629779 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
10x Genomics produces genomic analysis equipment, accelerating scientific research. The company is a key player in the biorevolution. The future revenue growth expectations reflected here are largely based on the technological breakthroughs made possible by 10x Genomics' products.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772570629795 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales TXG
This metric for 10x Genomics reflects revenue from sales of instruments and reagents for single-cell analysis, a revolutionary technology in biotechnology. Revenue is directly dependent on demand from research institutes and pharmaceutical companies. The growth in the graph demonstrates the widespread adoption of its technology for studying biology at a new level.
Sales of companies in the market segment - Dna
10x Genomics provides scientists with tools for analyzing biology at the single-cell level. Its revenue structure clearly demonstrates that its primary revenue comes from consumables for its instruments, not the instruments themselves. This is a classic "razor and blades" model, ensuring a stable and predictable income stream as its research base grows.
Overall market sales
10x Genomics, Inc. creates tools for analyzing biological systems at the cell level. The company is driving a revolution in biotechnology and medicine, with its growth driven by research and development. This graph of the overall economy shows the current state, while 10x Genomics' technologies offer insights into the future of healthcare.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company TXG
10x Genomics provides comprehensive solutions (instruments and software) for single-cell analysis, revolutionizing biotechnology. Demand for the company's products is driven by research spending in the scientific and pharmaceutical communities. This chart shows analyst sales forecasts, reflecting their confidence in the growth and adoption of single-cell analysis technology.
%20sales%20of%20the%20company%20TXG&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-TXG&v=1772570629906 "Schedule of future (projected) sales of the company TXG")
Future (projected) sales of companies in the market segment - Dna
10x Genomics, Inc. develops technologies for high-resolution analysis of biological systems, accelerating genomics research. This chart shows sales forecasts for the life sciences sector. Is investment in genomic research growing, creating a tailwind for equipment suppliers? This reflects overall scientific and commercial trends.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772570629987 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
10x Genomics produces tools and software for analyzing biological systems at the single-cell level. Demand for its products comes from academic and research institutions, driven by funding for science and biotech R&D. This graph is indirectly significant, as economic growth typically drives increased investment in science.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772570629993 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality TXG
10x Genomics produces innovative single-cell analysis systems that have revolutionized biological research. This chart illustrates the profitability of creating tools for scientific breakthroughs. The company's profitability depends on sales of its expensive instruments and consumables, the demand for which is growing as genomics and medicine advance.
Market segment marginality - Dna
10x Genomics, Inc. develops and produces tools and software for single-cell genomics. Its technologies enable scientists to make breakthroughs in biology and medicine. This metric reflects the financial health of a fast-growing, industry-leading company whose profitability depends on the rapid adoption of its technology in laboratories worldwide.
Market marginality as a whole
10x Genomics, Inc. creates tools for analyzing biological systems at the single-cell level. The company is at the forefront of biotechnology, and demand for its products depends on research funding. This overall profitability chart reflects the economic climate that impacts the budgets of research institutions and pharmaceutical companies.
Employees in the company, segment and market as a whole
Number of employees in the company TXG
10x Genomics produces equipment and reagents for genomic analysis at the single-cell level. Its team includes scientists, engineers, and sales specialists. This chart shows how the company invests in R&D to maintain its technological leadership and builds a commercial infrastructure to bring its sophisticated systems to scientific laboratories worldwide.
Share of the company's employees TXG within the market segment - Dna
10x Genomics provides cutting-edge tools for genomic and cellular analysis that have revolutionized biological research. Developing and manufacturing such sophisticated equipment requires a team of top scientists and engineers. This chart shows the company's labor market share, reflecting its leadership and ability to attract talent in the rapidly growing field of life sciences.
Number of employees in the market segment - Dna
10x Genomics produces tools for single-cell analysis, enabling scientists to gain unprecedented insight into biology. This graph shows employment in the genetic engineering sector. 10x Genomics' technologies are standard in many studies, and the growing number of scientists in this field directly translates into increased demand for their products.
Number of employees in the market as a whole
10x Genomics creates innovative tools for single-cell analysis, revolutionizing biology and medicine. The growth of its team of scientists and engineers is a testament to the advancement of cutting-edge science. Compared to the overall employment shown in this chart, 10x Genomics' hiring demonstrates the high demand for genomic research technologies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company TXG (TXG)
10x Genomics produces tools for genomic research. This chart demonstrates how highly the market values their technological leadership. Their sophisticated instruments and reagents have become industry standards. Their high market capitalization per employee reflects the value of their patents and dominant position in a rapidly growing market.
%20of%20the%20company%20TXG%20(TXG)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-TXG-TXG&v=1772570630215 "Chart of market capitalization per employee (in thousands of dollars) of the company TXG (TXG)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
10x Genomics (TXG) produces equipment and reagents for single-cell sequencing (analysis). Their technology has become the standard in life sciences R&D. This chart shows the industry average cost per employee. It helps estimate the premium the market pays for their breakthrough technology platform (instruments and consumables) per scientist.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772570630261 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
10x Genomics produces innovative equipment and reagents for genomic analysis. The company is a technological leader in its niche. The chart demonstrates a high valuation per employee, as its products enable scientists to make medical breakthroughs. The market values intellectual property and dominant position in a rapidly growing market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772570630289 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company TXG (TXG)
10x Genomics is a manufacturer of hardware and consumables for genomic research. The company sells tools to scientists. This chart shows how profitable the company is. High R&D costs to maintain leadership may put pressure on profits, but high consumable margins (the "razor and blades" model) should ensure high returns.
%20Chart%20TXG%20(TXG)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-TXG-TXG&v=1772570630307 "Company Profit Per Employee (in thousands of dollars) Chart TXG (TXG)")
Profit per employee (in thousands of dollars) in the market segment - Dna
10x Genomics (TXG) is a "Life Science Tools" company (equipment for single-cell genomics). This chart shows the benchmark for "DNA" (Life Science Tools). The average profit per employee here is high (or negative if it's R&D). It's a "razor and blades business." The benchmark reflects stable, high-margin revenue from "blades" (consumables).
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772570630340 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
10x Genomics (TXG) is a biotech company that produces equipment and consumables for single-cell analysis (reading genes in individual cells). It's a "razor blade business" for R&D. This chart shows how well the company sells its expensive equipment (razors) and, more importantly, its high-margin consumables (blades).
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772570630378 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee TXG (TXG)
10x Genomics produces innovative systems for single-cell analysis, revolutionizing biology. This chart demonstrates the demand for their unique technology. Their high revenue per employee reflects the high cost of their equipment and consumables, as well as their strong position in the rapidly growing genomics research market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-TXG-TXG&v=1772570630434 "Sales chart per company employee TXG (TXG)")
Sales per employee in the market segment - Dna
10x Genomics (TXG) produces cutting-edge equipment and reagents for single-cell analysis. They're the "spade" for the biotech gold rush. This chart shows the average output in the sector. For TXG, this is an indicator: how productive is their expensive R&D and sales team in creating and selling these complex scientific tools?
Sales per employee for the market as a whole
10x Genomics is a game-changer in biotechnology. They produce equipment and reagents (hardware and ink) for single-cell analysis, enabling scientists to make breakthroughs. This indicator demonstrates how scalable their high-tech R&D platform and manufacturing are to meet growing demand.
Short shares by company, segment and market as a whole
Shares shorted by company TXG (TXG)
10x Genomics (TXG) produces high-tech equipment and reagents for single-cell analysis. It's at the cutting edge of bioscience. This chart tracks short positions. Bears may believe the company's valuation is overvalued, the market for its equipment is saturated, or that research budgets (its clients) are shrinking.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-TXG-TXG&v=1772570630575 "Short Shares Chart for the Company TXG (TXG)")
Shares shorted by market segment - Dna
10x Genomics (TXG) is a leading life sciences tools company producing single-cell analysis equipment. This chart shows the total short position in the biotech equipment sector. It reflects investor concerns about a slowdown in biotech funding, which is reducing budgets.
Shares shorted by the overall market
10x Genomics (TXG) is a biotech company that produces R&D equipment. Their clients are biotech companies. This Short_All chart shows risk aversion. This pessimism is drying up venture capital funding for biotech companies (TXG's clients). Ultimately, they have no money left for R&D, which is killing TXG's main source of revenue.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator TXG (TXG)
10x Genomics (TXG) is a life sciences technology company. They produce tools and software (Chromium platform) for single-cell analysis, enabling scientists to explore biology at a new level. This chart measures hype. It shows "overbought" (above 70) amid biotech hype or "oversold" (below 30) amid research budget cuts.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-TXG-TXG&v=1772570630779 "RSI 14 indicator chart for the company's stock TXG (TXG)")
RSI 14 Market Segment - Dna
10x Genomics (TXG) is the "Rolls-Royce" of genomics. They sell "machines" (instruments) and "consumables" for single-cell analysis. The RSI_14_Seg for "Dna" (genomics) shows the "temperature" in this cutting-edge sector. The chart helps us understand: is TXG's growth driven by their technology, or is the entire sector overheated?
RSI 14 for the overall market
10x Genomics (TXG) sells R&D equipment to biotech companies. This chart tracks the pulse of its customers. In the euphoria of the moment, biotech companies are generously funded and buying up TXG's expensive consumables and equipment. In the panic, R&D funding dries up, and research budgets (TXG's lifeblood) are the first to be cut.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TXG (TXG)
10x Genomics is a leader in spatial biology and single-cell analysis. Their sophisticated instruments (Chromium, Visium) allow scientists to see biology in unprecedented resolution. This chart shows the average Wall Street price target. It's a collective bet on how quickly the scientific community will adopt this expensive technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TXG-TXG&v=1772570630929 "A chart showing analyst consensus forecasts for the expected stock price. TXG (TXG)")
The difference between the consensus estimate and the actual stock price TXG (TXG)
10x Genomics is a technology leader whose instruments (Chromium) and reagents enable scientists to analyze biology at the single-cell level. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their belief in revolutionizing biomedical R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TXG-TXG&v=1772570630984 "A chart showing the difference between the consensus forecast and the actual stock price. TXG (TXG)")
Analyst consensus forecast for stock prices by market segment - Dna
10x Genomics is a leader in single-cell sequencing and spatial biology. Their tools allow scientists to see biology with incredible resolution. This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe budgets for fundamental biological research will grow.
Analysts' consensus forecast for the overall market share price
10x Genomics (TXG) is a maker of 21st-century microscopes. Their instruments and reagents enable biologists to study individual cells (genomics), leading to medical breakthroughs. This chart reflects the overall risk appetite in the market. It shows how much analysts believe the economy can fund the expensive R&D projects that fuel TXG.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index TXG
10x Genomics is a leader in the revolutionary field of single-cell analysis. They provide the razor (instruments) and the blades (consumables) for biotech R&D. This chart is a summary indicator of their ecosystem. It likely measures not only instrument sales but, more importantly, the stable, high-margin consumable revenue generated by their growing installed base.
AKIMA Market Segment Index - Dna
10x Genomics (TXG) is the Rolls-Royce of life sciences; the company produces innovative equipment and consumables (Chromium technology) that enable scientists to analyze biology at the single-cell level. This aggregate metric evaluates companies. The graph shows the sector average. This benchmark: how much does 10x's technological leadership (and its razor-sharp model) differentiate it from the average medtech competitor?
The AKIM Index for the overall market
10x Genomics is a leader in single-cell analysis and spatial biology. Its tools enable scientists to see biology in ultra-high resolution. This chart, reflecting the market average, is the backdrop. It helps assess how this growth story, dependent on academic grants and pharmaceutical R&D budgets, compares to overall economic trends.
